Flupirtine (Maleate)

Flupirtine Maleate is a brain penetrant, and orally bioavailable, non-opioid and centrally acting analgesic agent. Flupirtine Maleate is an indirect N-methyl-D-aspartate receptor (NMDAR) antagonist. Neuroprotective properties[1][2].

Product Specifications

CAS Number

[75507-68-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

IGluR; Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Flupirtine-Maleate.html

Purity

99.97

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 1.43 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NC1=CC=C(N=C1N)NCC2=CC=C(C=C2)F)OCC.O=C(/C=C\C(O)=O)O

Molecular Formula

C19H21FN4O6

Molecular Weight

420.39

Precautions

H302, H315, H319, H335

References & Citations

[1]Jan Dörr, et al. Disease Modification in Multiple Sclerosis by Flupirtine-Results of a Randomized Placebo Controlled Phase II Trial. Front Neurol. 2018 Oct 9;9:842.|[2]Hanna M Jaeger, et al. The indirect NMDAR inhibitor flupirtine induces sustained post-ischemic recovery, neuroprotection and angioneurogenesis. Oncotarget. 2015 Jun 10;6 (16) :14033-44.|[3]Elango Panchanathan, Effect of flupirtine on the growth and viability of U373 malignant glioma cells.Cancer Biol Med. 2013 Sep;10 (3) :142-7.|[4]Martin J Gunthorpe, et al. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.Epilepsia. 2012 Mar;53 (3) :412-24.